Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 624

The DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.

Antidepressants in the Treatment of Neuropathic Pain

Open access
Sindrup, Søren H., Otto, Marit, Finnerup, Nanna B., Jensen, Troels S. · 2005 · Basic & Clinical Pharmacology & Toxicology

Abstract

Neuropathic pain is due to lesion or dysfunction of the peripheral or central nervous system. Tricyclic antidepressants and anticonvulsants have long been the mainstay of treatment of this type of pain. Tricyclic antidepressants may relieve neuropathic pain by their unique ability to inhibit presynaptic reuptake of the biogenic amines serotonin and noradrenaline, but other mechanisms such as N‐methyl‐D‐aspartate receptor and ion channel blockade probably also play a role in their pain‐relieving effect. The effect of tricyclic antidepressants in neuropathic pain in man has been demonstrated in numerous randomised, controlled trials, and a few trials have shown that serotonin noradrenaline and selective serotonin reuptake inhibitor antidepressants also relieve neuropathic pain although with lower efficacy. Tricyclic antidepressants will relieve one in every 2–3 patients with peripheral neuropathic pain, serotonin noradrenaline reuptake inhibitors one in every 4–5 and selective serotonin reuptake inhibitors one in every 7 patients. Thus, based on efficacy measures such as numbers needed to treat, tricyclic antidepressants tend to work better than the anticonvulsant gabapentin and treatment options such as tramadol and oxycodone, whereas the serotonin noradrenaline reuptake inhibitor venlafaxine appears to be equally effective with these drugs and selective serotonin reuptake inhibitors apparently have lower efficacy. Head‐to‐head comparisons between antidepressants and the other analgesics are lacking. Contraindications towards the use of tricyclic antidepressants and low tolerability in general of this drug class – may among the antidepressants – favour the use of the serotonin noradrenaline reuptake inhibitors. A recent study on bupropion, which is a noradrenaline and dopamine uptake inhibitor, indicated a surprisingly high efficacy of this drug in peripheral neuropathic pain. In conclusion, antidepressants represent useful tools in neuropathic pain treatment and must still be considered as first line treatments of neuropathic pain. However, without head‐to‐head comparisons between antidepressants and other analgesics, it is not possible to provide real evidence‐based treatment algorithms for neuropathic pain.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1742-7843.2005.pto_96696601.x

Cites

63 of 63 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 63 references

Cited by

See all 624

Metadata

Authors
Sindrup, S. H., Otto, M., Finnerup, N. B., & Jensen, T. S.
Venue
Basic & Clinical Pharmacology & Toxicology
Publisher
Wiley
Published
2005-06
Volume
96
Issue
6
Pages
399-409
ISSN
  • 1742-7835 (ISSN-L)
  • 1742-7843
OpenAlex
W2022835494
Cited by
624
References
63
FWCI
19.89
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Antidepressants in the Treatment of Neuropathic Pain. https://app.cochat.ai/papers/10.1111/j.1742-7843.2005.pto_96696601.x
The paper
Sindrup, S. H., Otto, M., Finnerup, N. B., & Jensen, T. S. (2005). Antidepressants in the Treatment of Neuropathic Pain. Basic & Clinical Pharmacology & Toxicology. https://doi.org/10.1111/j.1742-7843.2005.pto_96696601.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.